Cognito Therapeutics: Funding, Investors & Team (Sep 2026)
Cognito Therapeutics is a company that specializes in neurotechnology and is currently at the clinical stage. Its main aim is to develop pharmaceutical methods to treat neurodegenerative illnesses. The company's neuromodulation platform, which was created by scientific founders Li-Huei Tsai and Ed Boyden, is non-invasive. Their primary therapy is presently undergoing a significant study for Alzheimer's Disease and has been given FDA designation as a Breakthrough Device.
Cognito Therapeutics has raised $178M across 2 funding rounds on record, the most recent a Series C of $105M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cognito Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Cognito Therapeutics Funding Rounds
Cognito Therapeutics raised $73.0M in a Series B announced in Mar 2023.
3 years later, a Series C of $105M was announced in Mar 2026.
Cognito Therapeutics Founders and Leadership Team
Contact details for the Cognito Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Cognito Therapeutics Funding Compared to Other Biotechnology Startups
Cognito Therapeutics' latest round of $105M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cognito Therapeutics in Biotechnology and Cambridge
Companies Similar to Cognito Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Cognito Therapeutics Funding FAQs
What does Cognito Therapeutics do?
Cognito Therapeutics is a company that specializes in neurotechnology and is currently at the clinical stage. Its main aim is to develop pharmaceutical methods to treat neurodegenerative illnesses. The company's neuromodulation platform, which was created by scientific founders Li-Huei Tsai and Ed Boyden, is non-invasive. Their primary therapy is presently undergoing a significant study for Alzheimer's Disease and has been given FDA designation as a Breakthrough Device.
How much funding has Cognito Therapeutics raised?
Cognito Therapeutics has raised $178M across 2 rounds on record. The most recent is a Series C of $105M announced in Mar 2026.
When did Cognito Therapeutics last raise funding?
Cognito Therapeutics' most recent funding round on record is a Series C of $105M, announced in Mar 2026.
Who founded Cognito Therapeutics?
FundedIQ lists Christian Howell (Founder) at Cognito Therapeutics.
Who is the CEO of Cognito Therapeutics?
Brent Vaughan is listed as CEO at Cognito Therapeutics.
Where is Cognito Therapeutics headquartered?
Cognito Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Cognito Therapeutics have?
Cognito Therapeutics is in the 11-50 employee band.
How does Cognito Therapeutics' funding compare to other Biotechnology startups?
Cognito Therapeutics' latest round of $105M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Cognito Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cognito Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.